Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

作者：Willemijn J. Jansen, Olin Janssen, Betty M. Tijms, Stephanie J. B. Vos, Rik Ossenkoppele, Pieter Jelle Visser, Amyloid Biomarker Study Group, Dag Aarsland, Daniel Alcolea, Daniele Altomare, Christine A. F. Von Arnim, Simone Baiardi, Inês Baldeiras, Henryk Barthel, Randall J. Bateman, Bart van Berckel, Alexa Pichet Binette, Kaj Blennow, Merçé Boada, Henning Boecker, Michel Bottlaender, Anouk den Braber, David J. Brooks, Mark A. van Buchem, Vincent Camus, Jose Manuel Carill, Jiří Cerman, Kewei Chen, Gaël Chételat, Elena Chipi, Ann D. Cohen, Alisha Daniels, Marion Delarue, Mira Didic, Alexander Drzezga, Bruno Dubois, Marie Eckerström, Laura L. Ekblad, Sebastiaan Engelborghs, Stéphane Epelbaum, Anne M. Fagan, Yong Fan, Tormod Fladby, Adam Fleisher, Wiesje M. van der Flier, Stefan Förster, Juan Fortea, Kristian Steen Frederiksen, Yvonne Freund‐Levi, Lars Frings, Giovanni B. Frisoni, Lutz Fröhlich, Tomasz Gabryelewicz, Hermann‐Josef Gertz, Kiran Dip Gill, Olymbia Gkatzima, Estrella Gómez‐Tortosa, Timo Grimmer, Eric Guedj, Christian Habeck, Harald Hampel, Ron Handels, Oskar Hansson, Lucrezia Hausner, Sabine Hellwig, Michael T. Heneka, Sanna‐Kaisa Herukka, Helmut Hildebrandt, John R. Hodges, Jakub Hort, Chin‐Chang Huang, Ane Iriondo, Yoshiaki Itoh, Adrian Ivanoiu, William J. Jagust, Frank Jessen, Peter Johannsen, Keith A. Johnson, Ramesh Kandimalla, Elisabeth Kapaki, Silke Kern, Lena Kilander, Aleksandra Klimkowicz‐Mrowiec, William E. Klunk, Norman Koglin, Johannes Kornhuber, Milica G. Kramberger, Hung‐Chou Kuo, Koen Van Laere, Susan Landau, Brigitte Landeau, Dong Young Lee, Mony J. de Leon, Cristian E. Leyton, Kun‐Ju Lin, Alberto Lleó, Malin Löwenmark, Karine Madsen, Wolfgang Maier, Jan Marcusson, Marta Marquié, Pablo Martínez‐Lage, Nancy N. Maserejian, Niklas Mattsson, Alexandre de Mendonça, Philipp T. Meyer, Bruce L. Miller, Shinobu Minatani, Mark A. Mintun, Vincent Mok, José Luís Molinuevo, Silvia Morbelli, John C. Morris, Barbara Mroczko, Duk L. Na, Andrew B. Newberg, Flavio Nobili, Agneta Nordberg, Marcel G. M. Olde Rikkert, Catarina R. Oliveira, Pauline Olivieri, Adela Orellana, George P. Paraskevas, Piero Parchi, Matteo Pardini, Lucilla Parnetti, Oliver Peters, Judes Poirier, Julius Popp, Sudesh Prabhakar, Gil D. Rabinovici, Inez H. Ramakers, Lorena Rami, Eric M. Reiman, Juha O. Rinne, Karen M. Rodrigue, Eloy Rodríguez‐Rodríguez, Catherine M. Roe, Pedro Rosa‐Neto, Howard J. Rosen, Uroš Rot, Christopher C. Rowe, Eckart Rüther, Agustı́n Ruiz, Osama Sabri, Jayant Sakhardande, Pascual Sánchez‐Juan, Sigrid Botne Sando, Isabel Santana, Marie Sarazin, Philip Scheltens, Johannes Schröder, Per Selnes, Sang Won Seo, Dina Silva, Ingmar Skoog, Peter J. Snyder, Hilkka Soininen, Marc Sollberger, Reisa A. Sperling, L. Spiru, Yaakov Stern, Erik Stomrud, Akitoshi Takeda, Marc Teichmann, Charlotte E. Teunissen, Louisa I. Thompson, Jori Tomassen, Magda Tsolaki, Rik Vandenberghe, Marcel M. Verbeek, Frans R.J. Verhey, Victor L. Villemagne, Sylvia Villeneuve, Jonathan Vogelgsang, Gunhild Waldemar, Anders Wallin, Åsa K. Wallin, Jens Wiltfang, David A. Wolk, Tzu‐Chen Yen, Marzena Zboch, Henrik Zetterberg · 发表于：JAMA Neurology · 年份：2022 · DOI：10.1001/jamaneurol.2021.5216 · 被引用次数：300 · 研究领域：Dementia and Cognitive Impairment Research、Alzheimer's disease research and treatments、Intracerebral and Subarachnoid Hemorrhage Research

IMPORTANCE: One characteristic histopathological event in Alzheimer disease (AD) is cerebral amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and on positron emission tomography (PET) scans. Prevalence estimates of amyloid pathology are important for health care planning and clinical trial design. OBJECTIVE: To estimate the prevalence of amyloid abnormality in persons with normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia and to examine the potential implications of cutoff methods, biomarker modality (CSF or PET), age, sex, APOE genotype, educational level, geographical region, and dementia severity for these estimates. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional, individual-participant pooled study included participants from 85 Amyloid Biomarker Study cohorts. Data collection was performed from January 1, 2013, to December 31, 2020. Participants had normal cognition, subjective cognitive decline, mild cognitive impairment, or clinical AD dementia. Normal cognition and subjective cognitive decline were defined by normal scores on cognitive tests, with the presence of cognitive complaints defining subjective cognitive decline. Mild cognitive impairment and clinical AD dementia were diagnosed according to published criteria. EXPOSURES: Alzheimer disease biomarkers detected on PET or in CSF. MAIN OUTCOMES AND MEASURES: Amyloid measurements were dichotomized as normal or abnormal usi...